Neurocrine Biosciences, Inc. – NASDAQ:NBIX

Add to watchlist

$132.81

-6.62

-4.75%

Market closed

Open in 2 days

-5.42%

month

-5.42%

quarter

+5.03%

year

Market Cap	13.55B
Enterprise value	N/A

P/E	64.51
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	6.67
Price/Book	5.82
PEG ratio	0.90
EPS	3.76

Revenue	1.98B
EBITDA	482.3M
Income	369.7M
Revenue Q/Q	22.57%
Revenue Y/Y	23.99%

Profit margin	10.38%
Oper. margin	16.73%
Gross margin	98.44%
EBIT margin	16.73%
EBITDA margin	24.33%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Neurocrine Biosciences Stock Forecast

M Q Y

Last Year

$150.14

Potential upside: 13.05%

Analysts Price target
Financials & Ratios estimates

Neurocrine Biosciences, Inc. (NASDAQ:NBIX): Profit margin
Jun 2023	452.7M	95.5M	21.1%
Sep 2023	498.8M	83.1M	16.66%
Dec 2023	515.2M	147.7M	28.67%
Mar 2024	515.29M	43.4M	8.42%

Neurocrine Biosciences, Inc. (NASDAQ:NBIX): Debt to assets
Jun 2023	2613100000	760.1M	29.09%
Sep 2023	2848200000	846.1M	29.71%
Dec 2023	3251400000	1.01B	31.35%
Mar 2024	3472400000	1.08B	31.28%

Neurocrine Biosciences, Inc. (NASDAQ:NBIX): Cash Flow
Jun 2023	179.6M	-125.9M	2.9M
Sep 2023	212M	-97.3M	18.8M
Dec 2023	123.5M	-201.8M	35.4M
Mar 2024	130.3M	-55M	69.9M

Neurocrine Biosciences alternative data

Neurocrine Biosciences
Employees

Neurocrine Biosciences, Inc. (NASDAQ:NBIX): Employee count
Aug 2023	1,300
Sep 2023	1,350
Oct 2023	1,350
Nov 2023	1,350
Dec 2023	1,400
Jan 2024	1,400
Feb 2024	1,400
Mar 2024	1,400
Apr 2024	1,400
May 2024	1,400
Jun 2024	1,448
Jul 2024	1,448

Neurocrine Biosciences
Hedge Funds Holdings Q2 2022

90.73% -0.39%

of NBIX is owned by hedge funds

420 +9

hedge funds hold NBIX stock

88.55M -649.16K

shares is hold by hedge funds

NBIX hedge funds holdings changes

Neurocrine Biosciences
Insider Trading

Neurocrine Biosciences, Inc. (NASDAQ:NBIX): Insider trades (number of shares)
Period	Buy	Sel
Jan 2024	0	277731
Feb 2024	0	74279
Mar 2024	0	144521
Apr 2024	0	12859
May 2024	0	87358
Jul 2024	0	22863
Aug 2024	0	62964
Sep 2024	0	3461
Oct 2024	0	1295
Nov 2024	0	2331
Dec 2024	0	1091

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	17 Dec 2024	DELAET INGRID officer: Chief Regulatory Officer officer: Chief Regulatory Officer	Non-Qualified Stock Option	1,091	$79.02	$86,211
Sale	17 Dec 2024	DELAET INGRID officer: Chief Regulatory Officer officer: Chief Regulatory Officer	Common Stock	1,091	$135	$147,285
Option	17 Dec 2024	DELAET INGRID officer: Chief Regulatory Officer officer: Chief Regulatory Officer	Common Stock	1,091	$79.02	$86,211
Option	29 Nov 2024	ONYIA JUDE officer: Chief Scientific Officer officer: Chief Scientific Officer	Common Stock	4,426	N/A	N/A
Sale	29 Nov 2024	ONYIA JUDE officer: Chief Scientific Officer officer: Chief Scientific Officer	Common Stock	2,331	$126.29	$294,373
Option	29 Nov 2024	ONYIA JUDE officer: Chief Scientific Officer officer: Chief Scientific Officer	Restricted Stock Unit	4,426	N/A	N/A
Option	8 Nov 2024	ROBERTS EIRY officer: Chief Me..	Common Stock	1	$79.02	$79
Option	8 Nov 2024	ROBERTS EIRY officer: Chief Me..	Common Stock	971	$102.9	$99,916
Option	8 Nov 2024	ROBERTS EIRY officer: Chief Me..	Common Stock	1,233	$81.05	$99,935
Option	8 Nov 2024	ROBERTS EIRY officer: Chief Me..	Common Stock	5,140	$77.81	$399,943

NBIX insider trading transactions

Neurocrine Biosciences
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 1 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 7 Feb 2024	Q4 2023 Earnings Call Transcript
Q3 2023 31 Oct 2023	Q3 2023 Earnings Call Transcript
Q2 2023 1 Aug 2023	Q2 2023 Earnings Call Transcript

NBIX earnings call transcripts

Neurocrine Biosciences
Executives

Insider	Age	Compensation
Dr. Kevin C. Gorman Ph.D. (1958) Chief Executive Officer & Director	67	$1,380,000
Dr. Eiry Wyn Roberts (1964) Chief Medical Officer	61	$847,940
Mr. Matthew C. Abernethy (1980) Chief Financial Officer	45	$781,040
Mr. Eric S. Benevich (1965) Chief Commercial Officer	60	$748,830
Mr. Kyle W. Gano (1973) Chief Bus. Devel. and Strategy Officer	52	$711,720

Neurocrine Biosciences
Latest News

Friday, 20 December 2024
12:19	Neurocrine price target raised to $182 from $172 at BofA	https://thefly.com
08:00	Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia	prnewswire.com
Wednesday, 18 December 2024
10:11	Neurocrine Biosciences' Crenessity Approval Sets Stage For Diversified Revenue And Growth	seekingalpha.com
Friday, 13 December 2024
19:00	Neurocrine Wins FDA Approval For Genetic Disorder Drug	investors.com
18:55	Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia	prnewswire.com
17:50	US FDA approves Neurocrine Biosciences' genetic disorder drug	reuters.com
Tuesday, 26 November 2024
16:01	Neurocrine Biosciences to Participate at Investor Conferences in December	prnewswire.com
Friday, 8 November 2024
11:02	Why Neurocrine Biosciences Stock Is Very Attractive At Current Levels	seekingalpha.com
Thursday, 7 November 2024
08:30	Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules	prnewswire.com
Tuesday, 5 November 2024
16:01	Neurocrine Biosciences to Participate at Investor Conferences in November	prnewswire.com
Monday, 4 November 2024
08:30	Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules	prnewswire.com
08:25	Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia	prnewswire.com
Wednesday, 30 October 2024
15:11	Neurocrine Biosciences, Inc. (NBIX) Q3 2024 Earnings Call Transcript	seekingalpha.com
10:35	Neurocrine (NBIX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates	zacks.com
09:16	Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates	zacks.com
07:00	Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance	prnewswire.com
Wednesday, 23 October 2024
11:07	Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?	zacks.com
Thursday, 10 October 2024
07:42	Neurocrine: A Buy Amid CNS Pipeline Growth And Ingrezza's Strength (Rating Upgrade)	seekingalpha.com
Wednesday, 9 October 2024
16:01	Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results	prnewswire.com
Monday, 30 September 2024
08:30	Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use	prnewswire.com
Thursday, 19 September 2024
16:01	Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit	prnewswire.com
Thursday, 12 September 2024
16:31	Neurocrine's experimental drug misses primary goal in schizophrenia trial	reuters.com
16:05	Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia	prnewswire.com
Tuesday, 10 September 2024
16:01	Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference	prnewswire.com
Friday, 30 August 2024
07:41	Why Neurocrine Biosciences Stock Was Tumbling This Week	fool.com
Thursday, 29 August 2024
13:22	Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock	benzinga.com
12:37	Neurocrine Stock Down 19% on Mixed Schizophrenia Study Results	zacks.com
Wednesday, 28 August 2024
17:22	Neurocrine: Buying Opportunity After Stock Price Drop On Schizophrenia Data	seekingalpha.com
16:05	Neurocrine Biosciences to Participate at Investor Conferences in September	prnewswire.com
13:11	Neurocrine Biosciences: Disappointing Data From A Key Readout Hits The Stock Hard	seekingalpha.com

Frequently Asked Questions (FAQ)

What's the price of Neurocrine Biosciences stock today?

One share of Neurocrine Biosciences stock can currently be purchased for approximately $132.81.
When is Neurocrine Biosciences's next earnings date?

Unfortunately, Neurocrine Biosciences's (NBIX) next earnings date is currently unknown.
Does Neurocrine Biosciences pay dividends?

No, Neurocrine Biosciences does not pay dividends.
How much money does Neurocrine Biosciences make?

Neurocrine Biosciences has a market capitalization of 13.55B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 26.76% to 1.89B US dollars.
What is Neurocrine Biosciences's stock symbol?

Neurocrine Biosciences, Inc. is traded on the NASDAQ under the ticker symbol "NBIX".
What is Neurocrine Biosciences's primary industry?

Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
How do i buy shares of Neurocrine Biosciences?

Shares of Neurocrine Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Neurocrine Biosciences's key executives?
Neurocrine Biosciences's management team includes the following people:
- Dr. Kevin C. Gorman Ph.D. Chief Executive Officer & Director(age: 67, pay: $1,380,000)
- Dr. Eiry Wyn Roberts Chief Medical Officer(age: 61, pay: $847,940)
- Mr. Matthew C. Abernethy Chief Financial Officer(age: 45, pay: $781,040)
- Mr. Eric S. Benevich Chief Commercial Officer(age: 60, pay: $748,830)
- Mr. Kyle W. Gano Chief Bus. Devel. and Strategy Officer(age: 52, pay: $711,720)
How many employees does Neurocrine Biosciences have?

As Jul 2024, Neurocrine Biosciences employs 1,448 workers, which is 3% more then previous quarter.
When Neurocrine Biosciences went public?

Neurocrine Biosciences, Inc. is publicly traded company for more then 29 years since IPO on 23 May 1996.
What is Neurocrine Biosciences's official website?

The official website for Neurocrine Biosciences is neurocrine.com.
Where are Neurocrine Biosciences's headquarters?

Neurocrine Biosciences is headquartered at 12780 El Camino Real, San Diego, CA.
How can i contact Neurocrine Biosciences?

Neurocrine Biosciences's mailing address is 12780 El Camino Real, San Diego, CA and company can be reached via phone at 858 617 7600.
What is Neurocrine Biosciences stock forecast & price target?

Based on 6 Wall Street analysts` predicted price targets for Neurocrine Biosciences in the last 12 months, the avarage price target is $150.14. The average price target represents a 13.05% change from the last price of $132.81.

Neurocrine Biosciences, Inc.

neurocrine.com

Exchange:

NASDAQ

Full time employees:

1,700

Industry:

Drug Manufacturers - Specialty & Generic

Sector:

Healthcare

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.

858 617 7600

12780 El Camino Real
San Diego, CA 92130

CIK: 0000914475
ISIN: US64125C1099
CUSIP: 64125C109